Allogene Therapeutics, Inc.

ALLO

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001737287

SEC filings (opens in a new tab)

In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Allogene Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024 All holders in Q1 2024

13F holders of ALLO: Q1 2024 compared with Q2 2024
Measure	Q1 2024	Of which not filed for Q2 2024	Q2 2024	Change
Holders	161	1	175	+15
Shares	131.2M	93.5K	165.3M	+34.2M (+26.1%)
Value	$586.0M	$417.8K	$385.1M	−$200.5M (−34.2%)

1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (30)

Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to ALLO in Q2 2024
Institution	Shares	Value	% of portfolio
Capital World Investors	6,896,552	$16.1M	0.00%
Perceptive Advisors LLC	2,725,000	$6.35M	0.15%
Lynx1 Capital Management LP	2,228,295	$5.19M	1.87%
Jacobs Levy Equity Management, Inc	878,955	$2.05M	0.01%
Gsa Capital Partners LLP	835,342	$1.95M	0.14%
DAFNA Capital Management LLC	605,100	$1.41M	0.34%
Mirae Asset Global ETFs Holdings Ltd.	264,329	$617.6K	0.00%
Toroso Investments, LLC	236,536	$551.1K	0.01%
Squarepoint Ops LLC	126,628	$295.0K	0.00%
Russell Investments Group, Ltd.	80,197	$186.9K	0.00%
Public Employees Retirement System of Ohio	57,300	$133.5K	0.00%
Corebridge Financial, Inc.	56,578	$131.8K	0.00%
Bayesian Capital Management, LP	35,402	$82.5K	0.01%
AQR Capital Management LLC	27,287	$63.6K	0.00%
Schonfeld Strategic Advisors LLC	17,192	$40.1K	0.00%
Algert Global LLC	14,808	$34.5K	0.00%
Dynamic Technology Lab Private Ltd	14,085	$33.0K	0.00%
Phoenix Wealth Advisors	13,000	$30.3K	0.02%
State of Wisconsin Investment Board	12,870	$30.0K	0.00%
Federated Hermes, Inc.	12,300	$28.7K	0.00%
Atom Investors LP	10,833	$25.2K	0.00%
JustInvest LLC	10,399	$24.2K	0.00%
Amundi	8,011	$16.7K	0.00%
Itau Unibanco Holding S.A.	6,355	$14.8K	0.00%
Cullen/Frost Bankers, Inc.	1,315	$3.06K	0.00%
Nordwand Advisors, LLC	1,000	$2.33K	0.00%
Leonteq Securities AG	351	$818	0.00%
Abich Financial Wealth Management LLC	283	$659	0.00%
Parallel Advisors, LLC	221	$515	0.00%
CWM, LLC	61	$0	0.00%

Sold out (15)

Institutions that held Allogene Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of ALLO in Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
Octagon Capital Advisors LP	720,000	$3.22M
Zacks Investment Management	459,800	$2.06M
Nebula Research & Development LLC	115,988	$518.5K
Sherbrooke Park Advisers LLC	107,398	$480.1K
Harbor Capital Advisors, Inc.	96,837	$433.0K
American International Group, Inc.	46,567	$208.2K
Catalyst Funds Management Pty Ltd	39,400	$176.1K
XTX Topco Ltd	35,765	$159.9K
Headlands Technologies LLC	17,396	$77.8K
Metropolitan Life Insurance Co	3,664	$16.4K
Quadrant Capital Group LLC	1,414	$6.32K
Old Point Trust & Financial Services N A	500	$2.23K
NBC Securities, Inc.	200	$1.00K
Westend Capital Management, LLC	175	$782
Private Wealth Management Group, LLC	140	$626

Not filed for Q2 2024 yet (1)

Institutions that held Allogene Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ALLO in Q1 2024 that haven't filed for Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
Credit Suisse AG	93,461	$417.8K